# Evaluate Safety, Whole-Body Distribution and Radiation Dosimetry in Metastatic Castration Resistant Prostate Cancer

> **NCT06359821** · EARLY_PHASE1 · COMPLETED · sponsor: **Sichuan University** · enrollment: 4 (actual)

## Conditions studied

- Metastatic Prostate Cancer

## Interventions

- **DRUG:** ZA-001

## Key facts

- **NCT ID:** NCT06359821
- **Lead sponsor:** Sichuan University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-05-17
- **Primary completion:** 2024-10-14
- **Final completion:** 2024-10-14
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2025-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06359821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06359821, "Evaluate Safety, Whole-Body Distribution and Radiation Dosimetry in Metastatic Castration Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06359821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*